SYNTHEGO 802-30F MUT, iPSC TBX4 MUT
CIGLi001-A-1
General
Cell Line |
|
| hPSCreg name | CIGLi001-A-1 |
| Cite as: | CIGLi001-A-1 |
| Alternative name(s) |
SYNTHEGO 802-30F MUT, iPSC TBX4 MUT
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
CIGLi001-A (RPChiPS8023G1, iPSC TBX4 WT, StemRNA™ Human iPSC 802-3G, SYNTHEGO 802-30F) |
| Last update | 2nd February 2024 |
| Notes | This cell line is a subclone of CIGLi001-A and has a knockin mutation in the TBX4 gene in exon 3. The mutation: Ile119Asn fsX6 (ATT>AATT) heterozygous |
| User feedback | |
Provider |
|
| Generator | Center for Infection and Genomics of the Lung (CIGL) |
| Derivation country | United States |
External Databases |
|
| BioSamples | SAMEA114705109 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Additional restrictions:
Commercial use restrictions can be discussed with the supplier, SYNTHEGO |
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | Hispanic |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Family history | no |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
Whole genome sequencing
Passes test for quality control as mentioned by supplier vcf File: 802 30F datasheet.pdf The company, SYNTHEGO, that is supplying the cell line to us, mentions that quality control assessment is done and sequence validation data can be provided upon request |
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA114652490 |
Ethics
Also have a look at the ethics information for the parental line
CIGLi001-A
.
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | SYNTHEGO |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
CIGLi001-A.
|
|
| Passage number reprogrammed | 34 |
Reprogramming method |
|
| Vector type | None |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | SYNTHEGO edited the cell line using CRISPR with a single guide RNA. They used single-cell cloning using cell printer to isolate the clones. |
| Derived under xeno-free conditions |
Yes |
| Derived under GMP? |
Yes |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | iMatrix added in medium | ||||||
| Feeder cells |
No |
||||||
| Passage method |
Enzymatically
Accutase
|
||||||
| O2 Concentration | 21 % | ||||||
| CO2 Concentration | 5 % | ||||||
| Medium |
Other medium:
Base medium: StemMACS™ iPS-Brew XF, human
Main protein source: Serum concentration: 0 % Supplements
|
||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|||||
| SSEA-4 |
Yes |
|||||
| TRA 1-60 |
Yes |
| Marker | Present | Absent |
| mCpG | ||
| OCT4 | X |
Report
802 30F datasheet.pdf
Figure 4
| Pluripotency Score | Novelty Score | |
| 37.18372 | 1.282409 |
Report
802 30F datasheet.pdf
Table 1
Morphology pictures
802 30F datasheet.pdf
Figure 4 - The cells growing in colonies
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Certificate of Analysis |
|
| Is there a certificate of analysis available? |
Yes
Passage:
P19
|
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
Sanger sequencing
Mutation is confirmed according to the analysis done by SYNTHEGO. Alighment results can be provided upon request. vcf File: 802 30F datasheet.pdf The company, SYNTHEGO, that is supplying the cell line to us, mentions that quality control assessment is done and sequence validation data can be provided upon request
SNP typing array
KaryoStat+ indicates 802-30F cells are genomically stable vcf File: 802 30F datasheet.pdf Figure 1. KaryoStat+ indicates 802-30F cells are genomically stable.* KaryoStat+ results for wild type 802-30F cells (passage 19) indicate that genomic integrity is maintained. The whole-genome view displays all somatic and sex chromosomes in one frame with a high-level copy number. The smooth signal plot (right y-axis) is the smoothing of the log2 ratios which depict the signal intensities of probes on the microarray. A value of 2 represents a normal copy number state (CN = 2). A value of 3 represents chromosomal gain (CN = 3). A value of 1 represents a chromosomal loss (CN = 1). The pink, green and yellow colors indicate the raw signal for each individual chromosome probe, while the blue signal represents the normalized probe signal which is used to identify copy number and aberrations (if any). * descriptions adapted from Thermo Fisher Scientific. |
Genetic Modification
| Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.